|
|
Palmitoylethanolamide
Specific Recommendations:
News & Research:
Abstracts:
-
Palmitoylethanolamide for sleep disturbance. A double-blind, randomised,
placebo-controlled interventional study - Sleep Sci Pract 2021;5(1):12 -
"compared the efficacy and tolerability of 8 weeks of
daily supplemented PEA formulation (350 mg Levagen + ®) to a placebo ... At week
8, PEA supplementation reduced sleep onset latency, time to feel completely
awake and improved cognition on waking. After 8 weeks, both groups improved
their sleep quality and quantity scores similarly" - [Nutra
USA] - See palmitoylethanolamide at
Amazon.com.
-
Natural Products: Evidence
for Neuroprotection to Be Exploited in Glaucoma - Nutrients 2020 Oct 16 -
"Vitamins ... Vitamin A ... Vitamin B Complex ...
Vitamin C ... Vitamin D ... PUFAs ... Palmitoylethanolamide ... Melatonin ...
Citicoline ... Coenzyme Q10 ... Taurine ... Resveratrol ... Forskolin ...
Curcumin ... Lycium barbarum ... Saffron ... Erigeron breviscapus"
-
Effect of
palmitoylethanolamide on inner retinal function in glaucoma: a randomized,
single blind, crossover, clinical trial by pattern-electroretinogram - Sci
Rep 2020 Jun 26 - "Glaucoma is a neurodegenerative
disease, our study aimed to evaluate the potential effects of
Palmitoylethanolamide (PEA) supplementation on RGCs function by PERG
examination, and to record effects on intraocular pressure, visual field and
quality of life ... At baseline, most patients had an early visual field defect,
the IOP was well controlled. At the end of the PEA 600 mg supplementation, a
significantly higher (mean 0.56 μV, 95% CI 0.30-0.73, p < 0.001) in the P50-wave
amplitude was observed; in the PEA period a significantly lower IOP (- 1.6 mmHg,
95% CI - 2 to 1.2, p < 0.001) and higher quality of life scores (+ 6.7, 95% CI
4-9.9, p < 0.001) were observed. Our study is the first to show promising
effects of PEA on PERG and on quality of life in glaucoma patients"
-
Use of Topical
Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with
Antiglaucoma Medications - J Ocul Pharmacol Ther 2017 Nov -
"Chronic use of topical hypotensive therapies in
glaucoma patients leads to chronic inflammation of the ocular surface, which
decreases the success rate of long-term glaucoma management. The aim of this
study is to evaluate the effect of topical palmitoylethanolamide (PEA) (Defluxa©),
a well-known anti-inflammatory and analgesic agent, in suppressing the ocular
surface inflammation associated with the use of hypotensive eye drops ...
Compared to control, by day 15, the conjunctival hyperemia score was
significantly decreased in the PEA (Defluxa) group (P < 0.01), while the T-BUT
and the Schirmer Test achieved a significant improvement by day 30"
-
Effect of
palmitoylethanolamide on visual field damage progression in normal tension
glaucoma patients: results of an open-label six-month follow-up - J Med Food
2014 Sep;17 - "The purpose of this study is to assess
the effect of palmitoylethanolamide (PEA) oral administration on intraocular
pressure (IOP) and visual field damage progression in normal-tension glaucoma
(NTG) patients ... Visual field parameters significantly diminished in patients
receiving PEA compared to baseline values (-7.65±6.55 dB vs. -4.55±5.31 dB,
p<0.001; 5.21±4.08 dB vs. 3.81±3.02 dB ... systemic administration of PEA
reduces IOP and improves visual field indices in individuals affected by NTG"
-
Ocular hypotensive effect of
oral palmitoyl-ethanolamide: a clinical trial - Invest Ophthalmol Vis Sci
2011 Aug 3 - "intraocular pressure (IOP) in primary open
angle glaucoma (POAG) and ocular hypertension (OH) ... 42 patients with POAG or
OH who were treated with timolol 0.5% and whose IOP was between 19 and 24 mm Hg
received oral PEA (300-mg tablets twice a day) or placebo (PEA vehicle tablets
twice a day) for 2 months (period 1), and, after a 2-month washout, received the
other treatment for 1 month (period 2) ... After PEA treatment (mean baseline
IOP, 21.6 ± 1.7 mm Hg), IOP was reduced by 3.2 ± 1.3 mm Hg at 1 month and by 3.5
± 1.2 mm Hg (15.9% ± 5.1%) at 2 months (ANOVA, P < 0.001; both Tukey-Kramer, P <
0.01 vs. baseline); after placebo (mean baseline IOP, 21.5 ± 1.5 mm Hg), IOP was
reduced by 0.4 ± 1.2 mm Hg at 1 month and by 0.3 ± 1.3 mm Hg at 2 months (t-test
at both time points, P < 0.001 vs. PEA). No statistically significant vital
signs, visual field, visual acuity changes, or adverse events were detected in
either group"
|
|